Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

NCT05770895 PHASE1 COMPLETED Results posted

The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.

Details

Lead sponsor	Gilead Sciences
Phase	PHASE1
Status	COMPLETED
Enrolment	83
Start date	Mon Apr 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Hepatitis B

Interventions

• GS-2829
• GS-6779
• Placebo

Countries

New Zealand, Taiwan